RenalGuard system in high-risk patients for contrast-induced acute kidney injury

Carlo Briguori; Gabriella Visconti; Michael Donahue; Francesca De Micco; Amelia Focaccio; Bruno Golia; Giuseppe Signoriello; Carmine Ciardiello; Elvira Donnarumma; Gerolama Condorelli

doi:10.1016/j.ahj.2015.12.005

RenalGuard system in high-risk patients for contrast-induced acute kidney injury

Carlo Briguori, Gabriella Visconti, Michael Donahue, Francesca De Micco, Amelia Focaccio, Bruno Golia, Giuseppe Signoriello, Carmine Ciardiello, Elvira Donnarumma, Gerolama Condorelli

IRCCS SDN

Research output: Contribution to journal › Article

Abstract

Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m² and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P

Original language	English
Pages (from-to)	67-76
Number of pages	10
Journal	American Heart Journal
Volume	173
DOIs	https://doi.org/10.1016/j.ahj.2015.12.005
Publication status	Published - Mar 1 2016

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ahj.2015.12.005

Fingerprint Dive into the research topics of 'RenalGuard system in high-risk patients for contrast-induced acute kidney injury'. Together they form a unique fingerprint.

Cite this

Briguori, C., Visconti, G., Donahue, M., De Micco, F., Focaccio, A., Golia, B., Signoriello, G., Ciardiello, C., Donnarumma, E., & Condorelli, G. (2016). RenalGuard system in high-risk patients for contrast-induced acute kidney injury. American Heart Journal, 173, 67-76. https://doi.org/10.1016/j.ahj.2015.12.005

RenalGuard system in high-risk patients for contrast-induced acute kidney injury. / Briguori, Carlo; Visconti, Gabriella; Donahue, Michael; De Micco, Francesca; Focaccio, Amelia; Golia, Bruno; Signoriello, Giuseppe; Ciardiello, Carmine; Donnarumma, Elvira; Condorelli, Gerolama.

In: American Heart Journal, Vol. 173, 01.03.2016, p. 67-76.

Research output: Contribution to journal › Article

@article{4cba68d291834dcb905c96262c71b7be,

title = "RenalGuard system in high-risk patients for contrast-induced acute kidney injury",

abstract = "Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P ",

author = "Carlo Briguori and Gabriella Visconti and Michael Donahue and {De Micco}, Francesca and Amelia Focaccio and Bruno Golia and Giuseppe Signoriello and Carmine Ciardiello and Elvira Donnarumma and Gerolama Condorelli",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.ahj.2015.12.005",

language = "English",

volume = "173",

pages = "67--76",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - RenalGuard system in high-risk patients for contrast-induced acute kidney injury

AU - Briguori, Carlo

AU - Visconti, Gabriella

AU - Donahue, Michael

AU - De Micco, Francesca

AU - Focaccio, Amelia

AU - Golia, Bruno

AU - Signoriello, Giuseppe

AU - Ciardiello, Carmine

AU - Donnarumma, Elvira

AU - Condorelli, Gerolama

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P

AB - Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P

UR - http://www.scopus.com/inward/record.url?scp=84960343994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960343994&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2015.12.005

DO - 10.1016/j.ahj.2015.12.005

M3 - Article

C2 - 26920598

AN - SCOPUS:84960343994

VL - 173

SP - 67

EP - 76

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -